Hyphens Pharma International Limited, Singapore’s leading speciality pharmaceutical and consumer healthcare group, has announced a net profit of S$6.1m for the financial year ending 31 December 2025. Despite a 9.2% decline in overall revenue to S$177.4m, the company achieved historical highs in gross profit and margin, driven by strategic portfolio optimisation.
The company’s proprietary brands segment saw a significant 33.1% growth, bolstered by strong demand for Ceradan® dermatological products and Ocean Health® supplements. This growth was partially offset by declines in the Pharmaceutical and Medical Aesthetics segment, which experienced an 18.4% revenue drop due to factors such as lower sales in Vietnam and brand transitions.
Hyphens Pharma’s Executive Chairman and CEO, Lim See Wah, highlighted the company’s resilience in the face of macroeconomic challenges, including foreign exchange volatility and elevated operating costs. “Our FY2025 financial results reflect our ongoing efforts to improve the quality of our earnings as we optimise our product portfolios with a focus on higher margins,” he stated.
The Group also reported a strong net operating cash inflow of S$18.7m and proposed a final dividend of 1.5 Singapore cents per share for FY2025. Looking forward, Hyphens Pharma aims to continue enhancing its market access and penetration, particularly in its Proprietary Brands segment, whilst leveraging emerging technologies in its Digital Platform and e-Pharmacy segment.
As the company navigates external headwinds, it remains focused on execution, risk management, and long-term value creation, underscoring its commitment to sustaining growth and shareholder value.
